No evidence of a relation between 11β-hydroxysteroid dehydrogenase type 2 activity and salt sensitivity

American Journal of Hypertension

Volumn 16, Issue 9 I, 2003, Pages 729-733

  Melander, Olle ^a,c   Frandsen, Erik ^b   Groop, Leif ^a   Hulthén, U Lennart ^a  

^a LUND UNIVERSITY   (Sweden)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

11 hydroxysteroid dehydrogenase type 2; Cortisol and hypertension; Primary hypertension; Salt sensitivity

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALLOTETRAHYDROCORTISOL; HYDROCORTISONE DERIVATIVE; ISOENZYME; TETRAHYDROCORTISOL; TETRAHYDROCORTISONE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; PRIORITY JOURNAL; SALT INTAKE; SALT SENSITIVITY; URINE LEVEL; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; MIDDLE AGED; NATRIURESIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; SENSITIVITY AND SPECIFICITY; SODIUM INTAKE; STATISTICS; URINE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NATRIURESIS; PATIENT COMPLIANCE; SENSITIVITY AND SPECIFICITY; SODIUM, DIETARY; STATISTICS; TETRAHYDROCORTISOL;

EID: 1542496265     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(03)00981-6     Document Type: Article

References (19)

1. Ward R: Familial aggregation and genetic epidemiology of blood pressure, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management. New York, Raven Press, 1990, pp 81-100.
2. Elliott P, Stamler S, Nichols R, Dyer AR, Stamler R, Kesteloot H, Marmot M: Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group. BMJ 1996;312:1249-1253.
3. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3-10.
4. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS: Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension 1986;8:II127-II134.
5. Weinberger MH, Fineberg NS: Sodium and volume sensitivity of blood pressure: age and pressure change over time. Hypertension 1991;18:67-71.
6. Sharma AM, Schattenfroh S, Kribben A, Distler A: Reliability of salt-sensitivity testing in normotensive subjects. Klin Wochenschr 1989;67:632-634.
7. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM: Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987;237:268-275.
8. Edwards CRW, Stewart PM, Butt D, Brett L, McIntyre MA, Sutanto WS: Localization of 11β-hydroxysteroid dehydroganese: tissue specific protector of the mineralocorticoid receptor. Lancet 1988;2:986-989.
9. Funder JW, Pearce PT, Smith R, Smith AI: Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988;243:583-585.
10. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC: Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nat Genet 1995;10:394-399.
11. Stewart PM, Wallace AM, Valentino R, Shackleton CHL, Edwards CRE: Mineralocorticoid activity of liquorice: 11β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987;II:821-824.
12. Sigurjonsdottir HA, Ragnarsson J, Franzson L, Sigurdsson G: Is blood pressure commonly raised by moderate consumption of liquorice? J Hum Hypertens 1995;9:345-348.
13. Hamilton BP, Zadik Z, Edwin CM, Hamilton JH, Kowarski AA: Effect of adrenal suppression with dexamethasone in essential hypertension. J Clin Endocrinol Metab 1979;48:848-853.
14. Walker BR, Stewart PM, Shackleton CHL, Padfield PL, Edwards CRW: Deficient inactivation of cortisol by 11β-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol 1993;39:221-227.
15. Lovati E, Ferrari P, Dick B, Jostrandt K, Frey BM, Frey FJ, Schorr U, Sharma AM: Molecular basis of human salt sensitivity: the role of the 11β-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab 1999;84:3745-3749.
16. Melander O, Frandsen E, Groop L, Hulthen UL: Plasma ProANP(1-30) reflects salt sensitivity in subjects with heredity for hypertension. Hypertension 2002;39:996-999.
17. Shackleton CH, Whitney JO: Use of Sep-pak cartridges for urinary steroid extraction: evaluation of the method for use prior to gas chromatographic analysis. Clin Chim Acta 1980;107:231-243.
18. Palermo M, Shackelton CH, Mantero F, Stewart PM: Urinary free cortisone and the assessment of 11β-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol 1996;45:605-611.
19. Litchfield WR, Hunt SC, Jeunemaitre X, Fisher ND, Hopkins PN, Williams RR, Corvol P, Williams GH: Increased urinary free cortisol: a potential intermediate phenotype of essential hypertension. Hypertension 1998;31:569-574.